NBIX Latest Press Releases

-- August 12, 2026 --

Neurocrine Biosciences Announces Publication of KINECT-PRO Findings Demonstrating INGREZZA (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia PRNewswire 8:30 AM

-- August 7, 2026 --

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist PRNewswire 8:30 AM

-- July 30, 2026 --

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 23, 2026 --

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions PRNewswire 4:05 PM

-- July 21, 2026 --

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer PRNewswire 4:05 PM

-- July 9, 2026 --

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 1, 2026 --

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia PRNewswire 4:05 PM

-- June 15, 2026 --

Soleno Therapeutics Presents New VYKAT XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period PRNewswire 4:11 PM

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11-Hydroxylase Deficiency at ENDO 2026 PRNewswire 4:05 PM

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PRNewswire 8:35 AM

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 PRNewswire 8:30 AM

-- June 8, 2026 --

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA (valbenazine) Capsules Across a Broad Range of Patients PRNewswire 4:05 PM

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities PRNewswire 8:30 AM

-- June 3, 2026 --

Neurocrine Biosciences to Present New Two-Year CRENESSITY (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026 PRNewswire 8:30 AM

-- May 26, 2026 --

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June PRNewswire 4:01 PM

-- May 18, 2026 --

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA (valbenazine) Capsules PRNewswire 4:05 PM

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics PRNewswire 8:47 AM

-- May 14, 2026 --

4basebio Announces Appointment of Chief Financial Officer and Board Changes Globe Newswire 7:00 AM

-- May 5, 2026 --

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results PRNewswire 4:01 PM

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 PRNewswire 9:00 AM

-- May 4, 2026 --

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment PRNewswire 8:30 AM

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist PRNewswire 7:30 AM

-- May 1, 2026 --

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia PRNewswire 4:05 PM

-- April 29, 2026 --

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale PRNewswire 4:05 PM

-- April 22, 2026 --

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia PRNewswire 4:05 PM

-- April 14, 2026 --

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results PRNewswire 4:01 PM

Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA (valbenazine) Capsules Compared to AUSTEDO XR PRNewswire 8:30 AM

-- April 6, 2026 --

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio PRNewswire 7:00 AM

-- March 26, 2026 --

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings PRNewswire 8:30 AM

-- March 17, 2026 --

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer PRNewswire 4:05 PM